Chlamydia pneumoniae in atherosclerosis

Journal of Internal Medicine

Volumn 247, Issue 3, 2000, Pages 391-396

  Saikku, P ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Infection; Pathogenesis

Indexed keywords

ENDOTOXIN; HEAT SHOCK PROTEIN 60; LIPID; OUTER MEMBRANE PROTEIN;

ANTIGEN ANTIBODY COMPLEX; ANTIGENICITY; ATHEROGENESIS; ATHEROSCLEROSIS; BACTERIAL GROWTH; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; HUMAN; INFECTION; LIPID METABOLISM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANTIGENS, BACTERIAL; ARTERIOSCLEROSIS; CHAPERONIN 60; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; ENDOTOXINS; HUMANS;

EID: 0034127323     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2000.00659.x     Document Type: Conference Paper

References (66)

1. 1 Nieto FJ. Infections and atherosclerosis: New clues from an old hypothesis? Am J Epidemiol 1998; 148: 937-48.
2. 2 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
3. 3 Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-6.
4. 4 Grayston JT, Wang SP. History of Chlamydia Pneumoniae (TWAR). In: Allegra L, Blasi F, eds. Chlamydia pneumoniae. The Lung and the Heart. Milan: Springer, 1999; 1-8.
5. 5 Kuo CC, Jackson LA, Camphell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8: 451-61.
6. 6 Saikku P. Chlamydia pneumoniae - clinical spectrum. In: Stephens RS, et al., eds. Chlamydial Infections. San Francisco, USA: International Chlamydia Symposium, 1998; 145-54.
7. 7 Munōz B, West S. Trachoma. The forgotten cause of blindness. Epidemiol Rev 1997; 19: 205-17.
8. 8 von Hertzen L, Alakärppä H, Koskinen R, et al. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infection 1997; 118: 155-64.
9. 9 Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 1991; 266: 225-30.
10. 10 Saikku P. Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction. Eur Heart J 1993; 14(Suppl. 2): 62-5.
11. 11 Punnonen R, Terho P, Nikkanen V, Meurman O. Chlamydial serology in infertile women by immunofluorescence. Fertil Steril 1979; 31: 656-9.
12. 12 Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis 1985; 151: 832-9.
13. 13 Saikku P, Leinonen M, Mattila K, et al. Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; ii: 983-6.
14. 14 Kaukoranta-Tolvanen SS, Laitinen K, Saikku P, Leinonen M. Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microbial Pathogen 1994; 16: 313-9.
15. 15 Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614-20.
16. 16 Fryer RH, Schwobe EP, Woods ML, Rodgers GM. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 1997; 45: 168-74.
17. 17 Molestina RE, Miller RD, Ramirez JA, Summersgill JT. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect Immun 1999; 67: 1323-30.
18. 18 Taylor-Robinson D. Chlamydia pneumoniae in vascular tissue. Atherosclerosis 1998; 140(Suppl. 1): S21-4.
19. 19 Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
20. 20 Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes-The final report of the ROXIS study. Eur Heart J 1999; 20: 121-7.
21. 21 Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serologic evidence for Chlamydia pneumoniae infection. The azithromydicin in coronary artert disease: elimination of myocardial infection with chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-7.
22. 22 Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999; 281: 427-31.
23. 23 Blasi F, Consentini R, Raccanelli R, et al. A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest 1997; 112: 309-12.
24. 24 Mazzoli S, Tofani N, Fantini A, et al. Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J 1998; 135: 15-20.
25. 25 Hammerschlag MR. Chlamydia pneumoniae infections. Pediatr Infect Dis J 1993; 12: 260-1.
26. 26 Grayston JT, Golubjatnikov R, Hagiwara T, et al. Serologic tests for Chlamydia pneumoniae. Pediatr Infect Dis J 1993; 11: 790-1.
27. 27 Karvonen M, Tuomilehto J, Pitkäniemi J, Saikku P. The epidemic cycle of Chlamydia pneumoniae infection in eastern Finland between the years 1972 and 1987. Epidem Infect 1993: 110:349-60(Erratum, 1993: 111; 567).
28. 28 Kark J, Leinonen M, Paltiel O, Saikku P. Chlamydia pneumoniae and acute myocardial infarction in Jerusalem. Internat J Epidemiol 1997; 26: 730-8.
29. 29 Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Int Med 1992; 116: 273-8.
30. 30 Leinonen M, Linnanmäki E, Mattila K, et al. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microbial Pathogen 1990; 9: 67-73.
31. 31 Linnanmäki E, Leinonen M, Ekman MR, et al. Characterization of Chlamydia pneumoniae specific immune complexes in chronic coronary heart disease. Circulation 1993; 87: 1130-4.
32. 32 Glader CA, Boman J, Saikku P, Stenlund H, Dahlén GH. The proatherogenic properties of lipoprotein (a) may be enhanched through the formation of circulating immune complexes containing Chlamydia pneumoniae specific IgG antibodies. Eur Heart J 2000; 21: in press.
33. 33 Ward ME. The immunobiology and immunopathology of chlamydial infections. APMIS 1995; 103: 769-96.
34. 34 Kutlin A, Roblin PM, Hammerschlag MR. Continuous Chlamydia pneumoniae infection in vitro. In: Stephens RS, et al. eds. Chlamydial Infections. San Francisco, USA: International Chlamydia Symposium, 1998; 325-7.
35. 35 Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58: 686-99.
36. 36 Beatty WL, Byrne GI, Morrison RP. Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease. Trends Microbiol 1994; 2: 94-8.
37. 37 Valkonen K, Saikku P. Proteinase associated with. Chlamydia Pneumoniae. Proceedings of the 3rd Meeting of the European Society of Chlamydia Research, Vienna, 11-14 September. Bologna: Soc Editrica Esculapio, 1996; 41.
38. 38 Vehmaan-Kreula P, Puolakkainen M, Sarvas M, Welgus HG, Kovanen P. Membrane proteins of Chlamydia pneumoniae induce the secretion of 92 kDa gelatinase by human monocyte-derived macrophages. Proceedings of the 71st Congress of the European Atherosclerosis Society, Athens, May 26-29, 1999 (Abstract).
39. 39 Kalman S, Mitchell W, Marathe R, et al. Comparative genomes of Chlamydia Pneumoniae and C Trachomatis. Nature Gen 1999; 21: 385-9.
40. 40 Gaydos CA, Quinn TC, Bobo LD, Eiden JJ. Similarity of Chlamydia pneumoniae strains in the variable domain IV region of the major outer membrane protein gene. Infect Immun 1992; 60: 5319-23.
41. 41 Brade H, Brabetz W, Brade L, et al. Chlamydial lipopolysaccharide. J Endotoxin Res 1997; 4: 67-84.
42. 42 Richmond SJ, Stirling P. Localization of chlamydial group antigen in McCoy cell monolayers infected with Chlamydin trachomatis or Chlamydia psittaci. Infect Immun 1981; 34: 561-70.
43. 43 Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydin pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microbial Pathogen 1996; 21: 215-21.
44. 44 Molestina RE, Dean D, Miller RD, Ramirez JA, Summersgill JT. Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the omp 1 gene and biological activity in human endothelial cells. Infect Immun 1998; 66: 1370-6.
45. 45 Heinemann M, Susa M, Simnacher U, Marre R, Essig A. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Infect Immun 1996; 64: 4872-5.
46. 46 Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, Saikku P, Laitinen K. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microbial Pathogen 1996; 21: 407-11.
47. 47 Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998; 177: 725-9.
48. 48 Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 1998; 66: 5067-72.
49. 49 Morrison RP, Belland RJ, Lyng K, Caldwell HD. Chlamydial disease pathogenesis: the 57-kD chlamydial hypersensitivity antigen is a stress response protein. J Exp Med 1989; 170: 1271-83.
50. 50 Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation 1998; 98: 300-7.
51. 51 Kol A, Bourier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Investig 1999; 103: 571-7.
52. 52 Mayr M, Metzler B, Kiechl S,. et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Eschericia coli and Chlamydia pneumoniae. Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999; 99: 1560-6.
53. 53 Huittinen T, Laitinen Lounatmaa K, Puolakkainen M, Sarvas M, Leinonen M, Saikku P. Heat shock protein 60 is exposed on the surface of Chlamydia pneumoniae elementary bodies. Infect Dis Obstet Gynecol 1999; B: 103-4(Abstract).
54. 54 Huittinen T, Saikku P, Leinonen M, Chlamydia pneumoniae infection induces the development of antibodies to HSP60 in rabbits. Clin Microb Infect. 9th ECCMID Abstracts 1999; 5 (Suppl. 3): 69.
55. 55 Halme S, Saikku P, Surcel HM. Characterization of Chlamydia pneumoniae antigens using human T cell clones. Scand J Immunol 1997; 45: 378-64.
56. 56 Halme S, Syrjälä H, Bloigu A, et al. Lymphocyte responses to chlamydia antigens in patients with coronary heart disease. Eur Heart J 1997; 18: 1095-101.
57. 57 Mosorin M, Surcel HM, Laurila A, et al. Chlamydia pneumoniae reactive T lymphocytes in atherosclerotic plaque of carotid artery. In: Stephens RS, et al., eds. Chlamydial Infections. San Francisco, USA: International Chlamydia Symposium, 1998; 423-5.
58. 58 Bachmeier K, Neu N, de la Maza LM, Paö S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999; 283: 1335-9.
59. 59 Wesslén L, Påhlson C, Lindquist O, et al. An increase in sudden unexpected cardiac deaths among young Swedish orienteers during 1979-1992. Eur Heart J 1996; 17: 902-10.
60. 60 Campbell LA, Moazed TC, Kuo CC, Grayston JT. Preclinical models for Chlamydia pneumoniae and cardiovascular disease: hypercholesterolemic mice. Clin Microbiol Infect 1998; 4: S23-32.
61. 61 Laurila AL, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chlamydia pneumoniae antibodies and serum lipids in Finnish men: cross-sectional study. Br Med J 1997; 314: 1456-7.
62. 62 Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 2910-3.
63. 63 Murray LJ, O'reilly DPJ, Ong GML, O'neill C, Evans AE, Bamford KB. Chlmaydia pneumoniae antibodies are associated with an atherogenic lipid profile. Heart 1999; 81: 239-44.
64. 64 Cook PJ. Lip GYH, Davies P, Beevers DG, Wise R, Honeyborne D. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension 1998; 31: 589-94.
65. 65 Leinonen M, Saikku P. Interaction of Chlamydia pneumoniae with other risk factors of atherosclerosis. Am J Heart 1999; 138: S504-6.
66. 66 Stille W, Dittmann R, Justnubling G. Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae - a tentative hypothesis. Infection 1997; 25: 281-5.